摘要
目的探讨不同途径输注DC-CIK联合TACE对进展期肝细胞癌的治疗价值。方法自2011年3月1日—2014年1月1日,选取收治入院的进展期肝细胞癌146例,随机分成3组。A组51例,单纯行TACE治疗;B组46例,行TACE治疗+外周静脉回输DC-CIK细胞治疗;C组49例,行TACE治疗+肝动脉回输DC-CIK细胞治疗。观察治疗后AFP、肝功能、肿瘤进展情况、T细胞亚群变化、毒副作用及病人生存率情况。结果治疗后B组CD3+、CD4+和C组CD3+、CD4+、CD8+及CD4+/CD8+均高于A组和本组治疗前(P<0.05);B、C组间比较无显著差异(P>0.05)。A组和B组半年进展率、生存率比较无显著差异(P>0.05);C组与其余两组比较差异有统计学意义(P<0.05)。结论局部应用CIK联合TACE较全身应用CIK联合TACE是安全的方法,可提高治疗效果,延长患者生存期,具有一定的临床意义。
Objective To explore therapeutic value of different approaches of DC-CIK（ dendritic cell-cytokineinduced killer cells） infusion combined with TACE in treatment of aggressive-phase hepatocellular carcinoma. Methods A total of 146 inpatients with aggressive-phase hepatocellular carcinoma admitted during Mar 1,2011 and Jan 1,2014 were divided into group A（ n = 51） undergoing single TACE therapy,group B（ n = 46） undergoing TACE and peripheral vein return infusion of DC-CIK and group C（ n = 49） undergoing TACE and hepatic artery return infusion of DC-CIK.The conditions of AFP（ alpha-fetoprotein）,liver function,tumor progression,T-cell subset changes,toxic and sideeffect and survival rate of patients after the therapy were observed. Results The levels of CD3 and CD4 in group B and levels of CD3,CD4,CD8 and CD4 / CD8 after the therapy in group C were significantly higher than those in group A and those before the therapy in the same group（ P〈0. 05）; but the differences between group B and C were not statistically significant（ P〈0. 05）. The differences in progression and survival rates of six months between group A and B were not statistically significant（ P〈0. 05）; while the differences between group C and group A and B were statistically significant（ P〈0. 05）. Conclusion Local use of CIK-DC combined with TACE is safer than the total use of CIK-DC combined with TACE,and it can improve treatment effectiveness and increase life span of patients,which has certain clinical significance.
出处
《解放军医药杂志》
CAS
2015年第3期58-62,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
北京市科委"首都市民健康培育项目"(Z141100002114015)
关键词
肝肿瘤
树突细胞
细胞因子诱导杀伤细胞
输注
动脉内
输注
静脉内
Liver neoplasms
Dendritic cells
Cytokine-induced killer cells
Infusions
intra-arterial
Infusions
intravenous
